

CORRIGENDUM

DOI: 10.3892/ol.2017.6689

Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: A multicenter, observational retrospective study

JUAN MANUEL SEPÚLVEDA-SÁNCHEZ, ANTONIO CONDE-MORENO, MANUEL BARÓN, JAVIER PARDO, GASPAR REYNÉS and ANTONIO BELENGUER

Oncol Lett 13: 4093-4100, 2017; DOI: 10.3892/ol.2017.5988

Following the publication of this article, we have realized a couple of errors were included in the text, and would like to correct these for the record (the changed text is subsequently highlighted in bold).

First, on page 4,096, under the heading “*Treatment effectiveness*” at the end of the first paragraph, the text should have read as follows: “Similar results were observed after 6 months. Compared with the **3** months prior to lacosamide initiation, there was a significant reduction in total seizures **between 3 and 6 months** [prior to treatment, mean 26.4, SD 50.4, median 4.0 (range 0-200); **between 3 and 6 months**, mean 9.4, SD 22.8, median 0.5 (range 0-100); difference in means $P<0.0001$; Fig. 2].”

In addition, for Fig. 2, the y-axis title should have read as: “Mean number of seizures over the last **3** months”, and the figure legend should have read as follows: “Mean number of seizures **in the 3 months prior to, and during, the 3-6 month period** of lacosamide treatment in patients experiencing epileptic seizures due to a brain tumor (n=26). Numbers above the bars indicate the difference from the baseline and the corresponding P-value (calculated using the χ^2 test). NS, not significant.”

We regret any inconvenience these mistakes have caused.